Key Highlights

  • GeoVax Labs received a Nasdaq delisting determination after its bid price stayed below $1.00 for 30 consecutive Business days.
  • A 1-for-25 Reverse Stock Split in January 2026 cut outstanding shares from about 43.3 million to roughly 1.7 million.
  • The company's pipeline includes a GEO-CM04S1 COVID-19 Vaccine and a GEO-MVA mpox candidate positioned to advance toward Phase 3.

GeoVax Labs (NASDAQ: GOVX) enters September 2026 at a genuine crossroads. The clinical-stage vaccine and immunotherapy developer is racing to preserve its Nasdaq listing after receiving a delisting determination, even as it advances a pipeline spanning mpox, COVID-19 and oncology. For a company valued at only a few million dollars, the "next big signal" is less about a data readout than about whether its shares remain on a national exchange at all.

Company and Latest Development

GeoVax, based in Atlanta, develops vaccines and immunotherapies using its Modified Vaccinia Ankara (MVA) platform. On August 27, 2026, the company disclosed it had received a delisting determination from Nasdaq. According to its subsequent 8-K, GOVX's closing bid price stayed below the $1.00 minimum for 30 consecutive business days from July 16 through August 26, 2026, and the company had previously failed Nasdaq's minimum $2.5 million stockholders' Equity requirement. Nasdaq indicated trading would be suspended on September 8, 2026 unless GeoVax requested a hearing by September 3, 2026.

What Is Driving Attention Around GOVX?

The listing jeopardy is the dominant storyline. A 1-for-25 reverse stock split that took effect on January 12, 2026 was intended to restore compliance with the $1.00 bid rule, but it also made the company ineligible for a standard 180-day cure period, tightening the timeline. Market data show the stock still trading in early September, which would be consistent with a hearing request staying any suspension, but the outcome of that process is exactly the unresolved "signal" the market is awaiting. No verified clinical catalyst underlies the recent price action.

Key Numbers and Company Position

Following the reverse split, GeoVax's outstanding share count fell from roughly 43.3 million to about 1.7 million. The company has repeatedly turned to dilutive financings, and analysts have flagged tightening Capital resources and execution risk. On the pipeline, its GEO-CM04S1 COVID-19 vaccine has been studied across multiple Phase 2 trials in immunocompromised populations, including chronic lymphocytic leukemia patients and healthy boosters; its Gedeptin oncolytic program completed a Phase 1/2 study in advanced head and neck cancer; and its GEO-MVA mpox and smallpox candidate is positioned, based on European regulatory guidance, to advance toward Phase 3.

What Could Come Next?

The immediate binary is the Nasdaq hearing outcome and whether GOVX stays listed or moves to over-the-counter trading. Beyond that, investors may watch for further financings to satisfy the equity requirement, updates on the mpox Phase 3 plan, and additional COVID-19 vaccine data. Any new capital raise, partnership, or government or institutional funding for the mpox or COVID-19 programs could shape sentiment into the fourth quarter.

Risks to Watch

Delisting risk is acute and near-term; a suspension would reduce Liquidity and visibility. The company faces persistent funding pressure, and continued dilution through equity offerings is a material risk to existing holders. Clinical and Regulatory Risk remains across every program, and any of the trials could disappoint. A micro-cap valuation leaves the shares highly volatile and vulnerable to sharp swings on modest volume.

Conclusion

GeoVax is a small vaccine developer with a broad but capital-hungry pipeline, defined in the short term by its fight to stay on Nasdaq. With a delisting determination on the table and a hearing deadline in early September, the "next big signal" investors are waiting for is procedural as much as scientific. Whether GeoVax preserves its listing, secures fresh funding and keeps its mpox and COVID-19 programs moving will be the developments to monitor closely in the weeks ahead.